Cargando…

Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma

OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growt...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Haoqi, Wang, Xiaowen, Zhu, Wenfeng, Li, Yang, Yu, Zhenyu, Li, Hua, Yang, Yang, Zhu, Shuguang, Chen, Xiaolong, Wang, Genshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700990/
https://www.ncbi.nlm.nih.gov/pubmed/36434548
http://dx.doi.org/10.1186/s12893-022-01848-w
_version_ 1784839440853630976
author Chen, Haoqi
Wang, Xiaowen
Zhu, Wenfeng
Li, Yang
Yu, Zhenyu
Li, Hua
Yang, Yang
Zhu, Shuguang
Chen, Xiaolong
Wang, Genshu
author_facet Chen, Haoqi
Wang, Xiaowen
Zhu, Wenfeng
Li, Yang
Yu, Zhenyu
Li, Hua
Yang, Yang
Zhu, Shuguang
Chen, Xiaolong
Wang, Genshu
author_sort Chen, Haoqi
collection PubMed
description OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growth of the future liver remnant (FLR). METHODS: Twenty-four patients with HBV-associated HCC who underwent ALPPS in our hospital from August 2014 to January 2021 were retrospectively studied. Propensity score matching was used to compare oncologic outcomes of patients treated with ALPPS and transarterial chemoembolization (TACE). The expression of YAP and JNK in liver tissue after two stages of ALPPS were detected. RESULTS: The median standard liver volume (SLV) was 1471.4 ml. Before second stage of ALPPS, the median FLR increased by 74.4%, and the median FLR/SLV increased from 26.1 to 41.6%. Twenty-two patients (91.7%) received staged hepatectomy after a median interval of 15 (9–24) d. The total incidence of postoperative complications in ALPPS group was 54.5%, and of Clavien–Dindo ≥ IIIb postoperative complications (requiring surgical, endoscopic or radiological intervention under general anesthesia) was 9.1%. There was no significant difference in total complications between ALPPS group and TACE group, but there were lower rate of above grade III complications in the TACE group than that in the ALPPS group. The incidence of complications was lower in laparoscopic-ALPPS than that in open surgery. In ALPPS group, the 1-year, 2-year and 5-year overall survival rate were respectively 71.4%, 33.3% and 4.8%. Interval time was an independent risk factor associated with overall survival rate. There was no significant difference in overall survival rate between ALPPS group and TACE group. For advanced HCC (BCLC stage B and C), ALPPS group was not superior to TACE group in overall survival rate. The expression of YAP and p-JNK in the residual liver tissue after second stage procedure was higher than that after first stage procedure, and the co-expression of YAP and p-JNK was observed in the residual liver tissue. CONCLUSION: ALPPS is a safe and effective treatment for initially unresectable HBV-associated HCC. Laparoscopic technique might improve the effect of ALPPS. YAP and JNK pathway might take a role in rapid FLR increase in ALPPS procedure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-022-01848-w.
format Online
Article
Text
id pubmed-9700990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97009902022-11-27 Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma Chen, Haoqi Wang, Xiaowen Zhu, Wenfeng Li, Yang Yu, Zhenyu Li, Hua Yang, Yang Zhu, Shuguang Chen, Xiaolong Wang, Genshu BMC Surg Research OBJECTIVE: To evaluate the safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in the treatment of initially unresectable hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and to preliminarily explore the mechanism of rapid growth of the future liver remnant (FLR). METHODS: Twenty-four patients with HBV-associated HCC who underwent ALPPS in our hospital from August 2014 to January 2021 were retrospectively studied. Propensity score matching was used to compare oncologic outcomes of patients treated with ALPPS and transarterial chemoembolization (TACE). The expression of YAP and JNK in liver tissue after two stages of ALPPS were detected. RESULTS: The median standard liver volume (SLV) was 1471.4 ml. Before second stage of ALPPS, the median FLR increased by 74.4%, and the median FLR/SLV increased from 26.1 to 41.6%. Twenty-two patients (91.7%) received staged hepatectomy after a median interval of 15 (9–24) d. The total incidence of postoperative complications in ALPPS group was 54.5%, and of Clavien–Dindo ≥ IIIb postoperative complications (requiring surgical, endoscopic or radiological intervention under general anesthesia) was 9.1%. There was no significant difference in total complications between ALPPS group and TACE group, but there were lower rate of above grade III complications in the TACE group than that in the ALPPS group. The incidence of complications was lower in laparoscopic-ALPPS than that in open surgery. In ALPPS group, the 1-year, 2-year and 5-year overall survival rate were respectively 71.4%, 33.3% and 4.8%. Interval time was an independent risk factor associated with overall survival rate. There was no significant difference in overall survival rate between ALPPS group and TACE group. For advanced HCC (BCLC stage B and C), ALPPS group was not superior to TACE group in overall survival rate. The expression of YAP and p-JNK in the residual liver tissue after second stage procedure was higher than that after first stage procedure, and the co-expression of YAP and p-JNK was observed in the residual liver tissue. CONCLUSION: ALPPS is a safe and effective treatment for initially unresectable HBV-associated HCC. Laparoscopic technique might improve the effect of ALPPS. YAP and JNK pathway might take a role in rapid FLR increase in ALPPS procedure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12893-022-01848-w. BioMed Central 2022-11-24 /pmc/articles/PMC9700990/ /pubmed/36434548 http://dx.doi.org/10.1186/s12893-022-01848-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Haoqi
Wang, Xiaowen
Zhu, Wenfeng
Li, Yang
Yu, Zhenyu
Li, Hua
Yang, Yang
Zhu, Shuguang
Chen, Xiaolong
Wang, Genshu
Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title_full Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title_fullStr Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title_full_unstemmed Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title_short Application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
title_sort application of associating liver partition and portal vein ligation for staged hepatectomy for initially unresectable hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700990/
https://www.ncbi.nlm.nih.gov/pubmed/36434548
http://dx.doi.org/10.1186/s12893-022-01848-w
work_keys_str_mv AT chenhaoqi applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT wangxiaowen applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT zhuwenfeng applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT liyang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT yuzhenyu applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT lihua applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT yangyang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT zhushuguang applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT chenxiaolong applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma
AT wanggenshu applicationofassociatingliverpartitionandportalveinligationforstagedhepatectomyforinitiallyunresectablehepatocellularcarcinoma